New resource provides clear guidance on insurance, financing, grants, and medication savings programs to make family building more accessible
NORWALK, Conn., Nov. 25, 2025 /PRNewswire/ — Illume Fertility, a leading fertility practice in the tri-state area known for its award-winning medical team of expert physicians, patient-centered care, and advanced reproductive treatments enabling patients to achieve their fertility and family-building goals, has launched its new Finance Hub, a digital resource that helps patients understand and manage the financial side of fertility treatment.
With open enrollment underway and healthcare costs rising, the Finance Hub offers one convenient place for patients to explore insurance coverage, state mandates, treatment costs, financial aid, and advocacy resources. The goal is to remove the uncertainty that often prevents people from starting care and to empower them with clear, trustworthy information.
“Uncertainty about costs and coverage can prevent people from even taking the first step towards treatment,” said Dr. Mark Leondires, founder and medical director at Illume Fertility. “Our new Finance Hub gives patients the clarity they need to plan with confidence and take advantage of every available resource to make family building more accessible.”
The Finance Hub includes easy-to-navigate sections that address common financial questions prospective patients face, including:
Visitors can also download Illume’s IVF Grant Application Guide and Medication Savings Checklist, which provide step-by-step instructions for identifying financial assistance and maximizing savings on fertility medications.
As the end of the year approaches, Illume encourages patients to take advantage of their current insurance benefits before plans reset. This is also a smart time to prepare for 2026 treatment cycles.
For more information about Illume Fertility, visit our website.
About Illume Fertility
Illume Fertility is a leading fertility practice in the tri-state area providing a best-in-class patient experience and cutting-edge treatments by award-winning physicians to help patients achieve their fertility and family-building goals. Led by an expert team of nine highly credentialed, board-certified reproductive endocrinologists, many of whom have received Castle Connolly’s prestigious Top Doctors award, Illume Fertility specializes in a complete range of assisted reproductive technologies (ART) including intrauterine insemination (IUI), in vitro fertilization (IVF), preimplantation genetic testing (PGT) and egg, sperm, and embryo cryopreservation. Recognized as a Healthcare Equality Leader by the Human Rights Campaign for seven consecutive years, Illume Fertility’s commitment to inclusive care includes a world-renowned egg donation and gestational surrogacy program, a dedicated team of third-party reproduction experts, and Gay Parents To Be®, an award-winning resource hub offering tailored support for LGBTQ+ family building. Illume Fertility is the only regional fertility clinic with offices in Connecticut and New York offering comprehensive holistic support services, including in-house nutrition counseling, onsite genetic counselors, fertility acupuncture, yoga for fertility, community events, as well as a network of mental health providers focused on fertility and family-building. Illume Fertility is proud of its exceptional success rates including more than 2,000 surrogacy journeys and 18,000 babies welcomed, and continues to be a leader in patient-centered care, providing compassionate, expert guidance to each prospective parent we serve.
Media Contact
Stacy Callahan, Astonish Media Group, 917-972-1101, stacy@astonishmediagroup.com
SOURCE Illume Fertility
TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription…
Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January…
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern…
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard…
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the…